on May 28, 2007
Published online before print May 28, 2007, doi: 10.1161/CIRCULATIONAHA.106.671222
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 19, 2006
From the Center for the Evaluative Clinical Sciences (J.R.B., G.T.O.) and Departments of Medicine and of Community and Family Medicine (G.T.O.), Dartmouth Medical School, Hanover, NH, and Michigan Surgical Collaboration for Outcomes Research and Evaluation, University of Michigan, Ann Arbor (N.J.O.B.). * To whom correspondence should be addressed. E-mail: Jeremiah.Brown{at}Dartmouth.edu.
Background--Since the 1980s, antifibrinolytic therapies have assisted surgical teams in reducing the amount of blood loss. To date, however, serious questions remain regarding the safety and effectiveness of these agents. Methods and Results--We conducted a meta-analysis to compare aprotinin, Conclusions--All antifibrinolytic agents were effective in reducing blood loss and transfusion. There were no significant risks or benefits for mortality, stroke, myocardial infarction, or renal failure. However, high-dose aprotinin was associated with a statistically significant increased risk of renal dysfunction.
Accepted on March 26, 2007
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Jeremiah R. Brown PhD*,
-aminocaproic acid, and tranexamic acid with placebo and head to head on 8 clinical outcomes from 138 trials. Published randomized controlled trial data were collected from OVID/PubMed. Outcomes included total blood loss, transfusion of packed red blood cells, reexploration, mortality, stroke, myocardial infarction, dialysis-dependent renal failure, and renal dysfunction (0.5-mg/dL increase in creatinine from baseline). All agents were effective in significantly reducing blood loss by 226 to 348 mL and the proportion of patients transfused with packed red blood cells over placebo. Only high-dose aprotinin reduced the rate of reexploration (relative risk, 0.49; 95% CI, 0.33 to 0.73). There were no significant risks or benefits for any agent for mortality, stroke, myocardial infarction, or renal failure. However, high-dose aprotinin significantly increased the risk of renal dysfunction (relative risk, 1.47; 95% CI, 1.12 to 1.94), 12.9% versus 8.4%. Compared head to head, high-dose aprotinin demonstrated significant reduction in total blood loss over -aminocaproic acid (-184 mL; 95% CI, -256 to -112) and tranexamic acid (-195 mL; 95% CI, -286 to -105). There were no significant differences among any agent when compared head to head on other outcomes.
Key words: aminocaproic acids • aprotinin • meta-analysis • surgery • tranexamic acid
This article has been cited by other articles:
 |
|
 |
|
  J. R. Brown, C. A. Block, D. J. Malenka, G. T. O'Connor, A. C. Schoolwerth, and C. A. Thompson Sodium Bicarbonate Plus N-Acetylcysteine Prophylaxis: A Meta-Analysis J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1116 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 781 - 782. [Full Text] [PDF]
|
|
|
|
|
|
A. F.L. Later, J. J. Maas, F. H.M. Engbers, M. I.M. Versteegh, E. F. Bruggemans, R. A.E. Dion, and R. J.M. Klautz Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial Eur. J. Cardiothorac. Surg., August 1, 2009; 36(2): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Barnett, M. Liava'a, and P. D. Skillington Potential for benefits of aprotinin use to outweigh risks in patients undergoing the Ross procedure J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 233 - 234. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takagi, H. Manabe, N. Kawai, S.-n. Goto, and T. Umemoto Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 98 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Manrique, E. H. Jooste, B. A. Kuch, S. E. Lichtenstein, V. Morell, R. Munoz, D. Ellis, and P. J. Davis The Association of Renal Dysfunction and the Use of Aprotinin in Patients Undergoing Congenital Cardiac Surgery Requiring Cardiopulmonary Bypass Anesth. Analg., July 1, 2009; 109(1): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barnum and J. Sistino Renal dysfunction in cardiac surgery: identifying potential risk factors Perfusion, March 1, 2009; 24(2): 139 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Karkouti, D. N. Wijeysundera, T. M. Yau, J. L. Callum, D. C. Cheng, M. Crowther, J.-Y. Dupuis, S. E. Fremes, B. Kent, C. Laflamme, et al. Acute Kidney Injury After Cardiac Surgery: Focus on Modifiable Risk Factors Circulation, February 3, 2009; 119(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Henry MBChB, P. Carless BHSc MMedS, D. Fergusson PhD MHA, and A. Laupacis MD MSc The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis Can. Med. Assoc. J., January 20, 2009; 180(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Breuer, K. Martin, M. Wilhelm, G. Wiesner, C. Schreiber, J. Hess, R. Lange, and P. Tassani The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 167 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dietrich, M. Spannagl, J. Boehm, K. Hauner, S. Braun, T. Schuster, and R. Busley Tranexamic Acid and Aprotinin in Primary Cardiac Operations: An Analysis of 220 Cardiac Surgical Patients Treated with Tranexamic Acid or Aprotinin Anesth. Analg., November 1, 2008; 107(5): 1469 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wong, H. El Beheiry, Y. R. Rampersaud, S. Lewis, H. Ahn, Y. De Silva, A. Abrishami, N. Baig, R. J. McBroom, and F. Chung Tranexamic Acid Reduces Perioperative Blood Loss in Adult Patients Having Spinal Fusion Surgery Anesth. Analg., November 1, 2008; 107(5): 1479 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Ngaage, A. R. Cale, M. E. Cowen, S. Griffin, and L. Guvendik Aprotinin in Primary Cardiac Surgery: Operative Outcome of Propensity Score-Matched Study Ann. Thorac. Surg., October 1, 2008; 86(4): 1195 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Grant, Z. Kon, A. Joshi, E. Christenson, S. Kallam, N. Burris, J. Gu, and R. S. Poston Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery Bypass Ann. Thorac. Surg., September 1, 2008; 86(3): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Olenchock Jr, P. H.U. Lee, T. Yehoshua, S. A. Murphy, J. Symes, and G. Tolis Jr Impact of Aprotinin on Adverse Clinical Outcomes and Mortality up to 12 Years in a Registry of 3,337 Patients Ann. Thorac. Surg., August 1, 2008; 86(2): 560 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Karkouti and W. S. Beattie Letter by Karkouti and Beattie Regarding Article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients" Circulation, June 3, 2008; 117(22): e472 - e472. [Full Text] [PDF]
|
|
|
|
|
|
J. G.T. Augoustides Letter by Augoustides Regarding Article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients" Circulation, June 3, 2008; 117(22): e474 - e474. [Full Text] [PDF]
|
|
|
|
|
|
A. Levrat, A. Gros, L. Rugeri, K. Inaba, B. Floccard, C. Negrier, and J.-S. David Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients Br. J. Anaesth., June 1, 2008; 100(6): 792 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fergusson, P. C. Hebert, C. D. Mazer, S. Fremes, C. MacAdams, J. M. Murkin, K. Teoh, P. C. Duke, R. Arellano, M. A. Blajchman, et al. A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery N. Engl. J. Med., May 29, 2008; 358(22): 2319 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Bittner, J. Lemke, M. Lange, A. Rastan, and F. W. Mohr The Impact of Aprotinin on Blood Loss and Blood Transfusion in Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2008; 85(5): 1662 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Jones The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1707 - 1718. [Full Text] [PDF]
|
|
|
|
|
|
L. H. Edmunds Jr and R. W. Colman Bleeding That Won't Stop Ann. Thorac. Surg., April 1, 2008; 85(4): 1153 - 1154. [Full Text] [PDF]
|
|
|
|
|
|
D. Pagano, N. J. Howell, N. Freemantle, D. Cunningham, R. S. Bonser, T. R. Graham, J. Mascaro, S. J. Rooney, I. C. Wilson, R. Cramb, et al. Bleeding in cardiac surgery: The use of aprotinin does not affect survival J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schneeweiss, J. D. Seeger, J. Landon, and A. M. Walker Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death N. Engl. J. Med., February 21, 2008; 358(8): 771 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Shaw, M. Stafford-Smith, W. D. White, B. Phillips-Bute, M. Swaminathan, C. Milano, I. J. Welsby, S. Aronson, J. P. Mathew, E. D. Peterson, et al. The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting N. Engl. J. Med., February 21, 2008; 358(8): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.T. Augoustides Prolonged mechanical ventilation after cardiovascular surgery. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 463 - 464. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Bridges Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2790 - 2792. [Full Text] [PDF]
|
|